Wagner Charles F.'s most recent trade in TJX Companies, Inc. was a trade of 793 Deferred Stock Units done . Disclosure was reported to the exchange on June 10, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| TJX | Charles F. Wagner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 793 | 2,468 | - | - | Deferred Stock Units | |
| TJX | Charles F. Wagner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 793 | 2,468 | - | - | Deferred Stock Units | |
| TJX | Charles F. Wagner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 20 | 2,489 | - | - | Deferred Stock Units | |
| TJX | Charles F. Wagner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 20 | 2,489 | - | - | Deferred Stock Units | |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 500.00 per share. | 10 Mar 2025 | 3,298 | 51,671 (0%) | 0% | 500 | 1,649,000 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 479.61 per share. | 26 Feb 2025 | 4,962 | 54,969 (0%) | 0% | 479.6 | 2,379,825 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 483.28 per share. | 24 Feb 2025 | 3,310 | 59,931 (0%) | 0% | 483.3 | 1,599,657 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 463.46 per share. | 14 Feb 2025 | 2,293 | 63,241 (0%) | 0% | 463.5 | 1,062,714 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 6,655 | 65,534 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 467.98 per share. | 10 Feb 2025 | 2,649 | 58,879 (0%) | 0% | 468.0 | 1,239,679 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 10,262 | 54,414 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 7,114 | 61,528 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 518.27 per share. | 11 Nov 2024 | 3,000 | 44,137 (0%) | 0% | 518.3 | 1,554,810 | Common Stock |
| TJX | Charles F. Wagner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2024 | 944 | 1,665 | - | - | Deferred Stock Units | |
| TJX | Charles F. Wagner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2024 | 944 | 1,665 | - | - | Deferred Stock Units | |
| TJX | Charles F. Wagner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2024 | 9 | 1,675 | - | - | Deferred Stock Units | |
| TJX | Charles F. Wagner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2024 | 9 | 1,675 | - | - | Deferred Stock Units | |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 460.00 per share. | 03 Jun 2024 | 3,250 | 47,137 (0%) | 0% | 460 | 1,495,000 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 454.79 per share. | 28 May 2024 | 3,250 | 50,387 (0%) | 0% | 454.8 | 1,478,068 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 431.79 per share. | 23 Feb 2024 | 3,309 | 53,583 (0%) | 0% | 431.8 | 1,428,793 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 424.01 per share. | 16 Feb 2024 | 3,750 | 59,704 (0%) | 0% | 424.0 | 1,590,038 | Common Stock |
| Vertex Pharma | F. Wagner Charles | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 420.58 per share. | 16 Feb 2024 | 2,812 | 56,892 (0%) | 0% | 420.6 | 1,182,671 | Common Stock |
| Vertex Pharma | Charles Wagner F. | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 422.74 per share. | 09 Feb 2024 | 2,607 | 63,454 (0%) | 0% | 422.7 | 1,102,083 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 9,440 | 58,947 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Wagner F. Charles | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 7,114 | 66,061 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | F. Wagner Charles | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 5,814 | 49,507 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Wagner Charles F. | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 405.00 per share. | 02 Jan 2024 | 3,000 | 43,693 (0%) | 0% | 405 | 1,215,000 | Common Stock |
| TJX | Charles F. Wagner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Sep 2023 | 721 | 721 | - | - | Deferred Stock Units | |
| TJX | Charles F. Wagner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Sep 2023 | 721 | 721 | - | - | Deferred Stock Units | |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 305.38 per share. | 24 Mar 2023 | 1,768 | 49,611 (0%) | 0% | 305.4 | 539,912 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 295.43 per share. | 17 Mar 2023 | 784 | 52,235 (0%) | 0% | 295.4 | 231,617 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 298.09 per share. | 17 Mar 2023 | 360 | 51,635 (0%) | 0% | 298.1 | 107,312 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 294.52 per share. | 17 Mar 2023 | 360 | 53,019 (0%) | 0% | 294.5 | 106,027 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 299.58 per share. | 17 Mar 2023 | 240 | 51,395 (0%) | 0% | 299.6 | 71,899 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 296.30 per share. | 17 Mar 2023 | 240 | 51,995 (0%) | 0% | 296.3 | 71,112 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 301.12 per share. | 17 Mar 2023 | 16 | 51,379 (0%) | 0% | 301.1 | 4,818 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 293.35 per share. | 10 Mar 2023 | 1,153 | 54,448 (0%) | 0% | 293.4 | 338,233 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 294.52 per share. | 10 Mar 2023 | 715 | 53,733 (0%) | 0% | 294.5 | 210,582 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 291.47 per share. | 10 Mar 2023 | 541 | 56,359 (0%) | 0% | 291.5 | 157,685 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 287.83 per share. | 10 Mar 2023 | 515 | 57,257 (0%) | 0% | 287.8 | 148,232 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 292.41 per share. | 10 Mar 2023 | 420 | 55,061 (0%) | 0% | 292.4 | 122,812 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 286.64 per share. | 10 Mar 2023 | 361 | 57,772 (0%) | 0% | 286.6 | 103,477 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 288.91 per share. | 10 Mar 2023 | 327 | 56,930 (0%) | 0% | 288.9 | 94,474 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 295.89 per share. | 10 Mar 2023 | 292 | 53,441 (0%) | 0% | 295.9 | 86,400 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 292.68 per share. | 10 Mar 2023 | 185 | 56,174 (0%) | 0% | 292.7 | 54,146 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 294.94 per share. | 10 Mar 2023 | 102 | 56,045 (0%) | 0% | 294.9 | 30,084 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 296.77 per share. | 10 Mar 2023 | 62 | 53,379 (0%) | 0% | 296.8 | 18,400 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 289.43 per share. | 10 Mar 2023 | 30 | 56,900 (0%) | 0% | 289.4 | 8,683 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 293.59 per share. | 10 Mar 2023 | 27 | 56,147 (0%) | 0% | 293.6 | 7,927 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 288.29 per share. | 10 Mar 2023 | 24 | 56,021 (0%) | 0% | 288.3 | 6,919 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 289.12 per share. | 24 Feb 2023 | 3,308 | 58,133 (0%) | 0% | 289.1 | 956,409 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 292.85 per share. | 17 Feb 2023 | 3,750 | 61,441 (0%) | 0% | 292.9 | 1,098,188 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 298.26 per share. | 10 Feb 2023 | 4,992 | 65,191 (0%) | 0% | 298.3 | 1,488,914 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 294.33 per share. | 10 Feb 2023 | 2,707 | 70,183 (0%) | 0% | 294.3 | 796,751 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 10,324 | 53,188 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 10,262 | 63,450 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 9,440 | 72,890 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 257.18 per share. | 02 May 2022 | 100 | 42,953 (0%) | 0% | 257.2 | 25,718 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 259.45 per share. | 02 May 2022 | 80 | 42,813 (0%) | 0% | 259.5 | 20,756 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 258.22 per share. | 02 May 2022 | 60 | 42,893 (0%) | 0% | 258.2 | 15,493 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 261.15 per share. | 02 May 2022 | 48 | 42,765 (0%) | 0% | 261.1 | 12,535 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 262.06 per share. | 02 May 2022 | 32 | 42,733 (0%) | 0% | 262.1 | 8,386 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 254.85 per share. | 02 May 2022 | 20 | 43,053 (0%) | 0% | 254.9 | 5,097 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 264.33 per share. | 02 May 2022 | 3 | 42,730 (0%) | 0% | 264.3 | 793 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 276.17 per share. | 29 Apr 2022 | 547 | 43,073 (0%) | 0% | 276.2 | 151,065 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 265.06 per share. | 01 Apr 2022 | 1,142 | 44,379 (0%) | 0% | 265.1 | 302,699 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 265.95 per share. | 01 Apr 2022 | 536 | 43,843 (0%) | 0% | 265.9 | 142,549 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 263.67 per share. | 01 Apr 2022 | 381 | 45,521 (0%) | 0% | 263.7 | 100,458 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 261.42 per share. | 01 Apr 2022 | 300 | 45,902 (0%) | 0% | 261.4 | 78,426 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 266.68 per share. | 01 Apr 2022 | 223 | 43,620 (0%) | 0% | 266.7 | 59,470 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 250.13 per share. | 17 Mar 2022 | 3,110 | 46,263 (0%) | 0% | 250.1 | 777,904 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 251.05 per share. | 17 Mar 2022 | 61 | 46,202 (0%) | 0% | 251.0 | 15,314 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 227.86 per share. | 24 Feb 2022 | 2,189 | 49,373 (0%) | 0% | 227.9 | 498,786 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 232.51 per share. | 17 Feb 2022 | 3,439 | 51,562 (0%) | 0% | 232.5 | 799,602 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 237.74 per share. | 10 Feb 2022 | 2,434 | 55,001 (0%) | 0% | 237.7 | 578,659 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 11,628 | 50,117 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 10,262 | 60,379 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 3,698 | 38,489 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 250.07 per share. | 01 Feb 2022 | 2,944 | 57,435 (0%) | 0% | 250.1 | 736,206 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 217.21 per share. | 30 Apr 2021 | 547 | 34,679 (0%) | 0% | 217.2 | 118,814 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 217.57 per share. | 24 Feb 2021 | 547 | 35,226 (0%) | 0% | 217.6 | 119,011 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 214.16 per share. | 10 Feb 2021 | 2,365 | 35,773 (0%) | 0% | 214.2 | 506,488 | Common Stock |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2021 | 11,627 | 38,138 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Charles F. Wagner | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2021 | 10,324 | 26,511 (0%) | 0% | 0 | Common Stock |